The Genomic Landscape and Its Clinical Implication in NPM1-Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

净现值1 米多司他林 奥佐美星 医学 肿瘤科 内科学 CEBPA公司 髓系白血病 突变 CD33 遗传学 生物 基因 干细胞 核型 染色体 川地34
作者
Sibylle Cocciardi,Nina Weiß,Maral Saadati,Sabrina Skambraks,Daniela Weber,Isabelle Schneider,Annika Meid,Sophia Aicher,Kathrin Bengesser-Kuhn,Andrea Corbacioglu,Verena I. Gaidzik,Frauke Theis,Walter Fiedler,Michael W.M. Kühn,Ulrich Germing,Karin Mayer,Michael Lübbert,Felicitas Thol,Michael Heuser,Arnold Ganser
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4311-4311 被引量:3
标识
DOI:10.1182/blood-2023-185566
摘要

Background: Mutations in the Nucleophosmin 1 gene ( NPM1 mut ) represent one of the most common genetic lesions in acute myeloid leukemia (AML).Based on its characteristic clinico-pathologic features, NPM1 mutAML has been recognized as a distinct entity among the category “AML with recurrent genetic abnormalities”. According to the ELN 2022 genetic risk-stratification, NPM1 mut AML, in the absence of FLT3-ITD mutation, is associated with a favorable prognosis. However, a significant proportion of these patients (pts) relapse after intensive therapy suggesting that other co-mutations may have an impact on outcome. Aims: To comprehensively characterize the genomic landscape and leukemogenic trajectoriesin a large cohort of NPM1 mut AML pts and to investigate its prognostic and predictive impact on outcome. Methods: Targeted DNA sequencing (mean read depth: 1817) on the entire coding region of 263 genes was performed in 568 NPM1 mut AML pts (median age: 58.7 years; 18-60 years, n=317; >60 years, n=251). All pts were enrolled in the randomized open-label Phase 3 AMLSG 09-09 trial [NCT00893399; Döhner H et al. Lancet Haematol 2023]. In this trial, pts were assigned to intensive chemotherapy plus all- trans retinoic acid with or without gemtuzumab ozogamicin; none of the pts received midostaurin. Results: In total n=3,058 variants (variant allele frequency of ≥1%) were identified in 195/263 genes. The median number of co-mutations was 3 (range 0-11). The most common co-mutated genes were DNMT3A (49.5%), FLT3-TKD (42.8%) PTPN11 (24.8%), NRAS (22.7%) TET2 (21.7%), IDH2 (21.3%), IDH1 (18%), and FLT3-ITD (17.3%). DNMT3AR882 hotspot mutations occurred more frequently in younger pts (36.6% vs 17.1%), while there was no difference for DNMT3AnonR882 mutations between the two age groups (21.8% and 21.9%). An age-dependent difference was also identified for mutations in myelodysplasia-related genes ( ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2) as defined by the ICC, occurring with a higher incidence in older pts (30.3% vs 12.3% in younger pts). Analyzing the mutational pattern of co-mutations, we found statistically significant tertiary gene-gene interactions: e.g., NPM1- NFE2- STAG2 (p<.001), NPM1- IDH2- SRSF2 (p<.001), NPM1- CEBPA- TET2 (p<.001), NPM1- DNMT3AR882- NRAS (p=.002), and NPM1- ASXL1- SRSF2 (p=.004); mutual exclusivities were identified for NPM1- DNMT3AR882- DNMT3AnonR882 (p<.001), NPM1- IDH2- TET2 (p<.001), NPM1- DNMT3AR882- SRSF2 (p<.001), NPM1- IDH1- TET2 (p<.001), and NPM1- FLT3-ITD- KRAS (p<.002). Correlating co-mutation data with outcome, we found that DNMT3AR882 hotspot mutations confer inferior event-free (EFS) and overall survival (OS) only in younger pts (EFS, p<.001 vs p=.11, Figure 1a; OS, p=.003 vs p=.8), whereas DNMT3AnonR882 mutations did not impact prognosis within the two age groups. We also found a negative prognostic impact of IDH1 mutations which was restricted to younger pts (EFS, p=.05), whereas IDH2 mutations were associated with superior EFS in older pts (p=.04) and superior OS in both groups (p=.05 and p=.03). Of note, co-mutations occurring in one or more of the myelodysplasia-related genes did not impact EFS or OS (Figure 1b). In multivariable analysis (all pts) including age, WBC, LDH, allogeneic transplantation in CR1, and mutations with an incidence of at least 3% as covariables, age (HR,1.03; p<.001), DNMT3AR882 (HR, 1.86; p<.001), FLT3-ITD (HR, 1.54; p=.012), IDH1 (HR, 1.48; p=.009), MYC (HR, 1.83; p=.032), and WT1 (HR, 1.73; p=.012), were associated with an inferior EFS, while SMC3 mutation showed favorable EFS (HR, 0.44; p=.019). To further study the leukemogenic trajectories, we used an oncogenetic tree modeling algorithm, which yielded a tree with several main branches including DNMT3AR882, DNMT3AnonR882, FLT3-TKD , IDH1, IDH2, PTPN11, and TET2. These mutations might represent initiating events which predispose to additional events with further distinct branches. Conclusions: Our study provides comprehensive data on the genomic landscape and its clinical impact in pts with NPM1mut AML fit for intensive chemotherapy. The co-mutational pattern clearly differs between younger and older NPM1 mutAML pts. Using this large dataset allowed the identification of secondary and tertiary gene-gene interactions with significant impact on outcome. Further data analysis is ongoing and will be presented at the meeting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苏11发布了新的文献求助10
刚刚
下载驳回了march的应助
刚刚
刚刚
轩乔发布了新的文献求助10
1秒前
2秒前
噜噜噜完成签到 ,获得积分20
2秒前
观澜完成签到 ,获得积分10
2秒前
旺旺小福星完成签到 ,获得积分10
3秒前
文艺点点完成签到,获得积分10
3秒前
机智的香菇完成签到,获得积分10
3秒前
chuangLiu发布了新的文献求助10
4秒前
4秒前
5秒前
6秒前
chenqj发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
Caius完成签到 ,获得积分10
8秒前
Sci666完成签到 ,获得积分10
9秒前
yaro完成签到,获得积分10
9秒前
10秒前
流萤完成签到,获得积分10
10秒前
10秒前
阿白发布了新的文献求助10
11秒前
11秒前
mrjohn发布了新的文献求助10
11秒前
orixero的应助被苏邑采纳,获得10
11秒前
flexiblemonkeys完成签到,获得积分10
12秒前
风吹麦浪的应助被名古邬采纳,获得20
13秒前
orixero的应助被Rainvin采纳,获得10
14秒前
自信的牛排完成签到 ,获得积分10
14秒前
fdyy1完成签到,获得积分10
15秒前
漫漫发布了新的文献求助10
15秒前
姜OMG发布了新的文献求助10
15秒前
cgliuhx发布了新的文献求助10
15秒前
QQ发布了新的文献求助10
15秒前
小小发布了新的文献求助10
16秒前
Dee完成签到,获得积分10
16秒前
所所的应助被Re采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527